What is QBREXZA?
QBREXZA (glycopyrronium) is a prescription medication used for the treatment of excessive underarm sweating, also known as primary axillary hyperhidrosis. It is a topical anticholinergic medication that is applied directly to the skin using a cloth, and works by blocking the production of sweat in the treated area. QBREXZA is manufactured by Dermira, Inc. and was approved by the U.S. Food and Drug Administration (FDA) in June 2018.
QBREXZA comes in the form of a cloth that is pre-moistened with the medication and is intended for single use. The cloth should be used to apply the medication to clean, dry skin in the underarm area once daily, and then disposed of in accordance with the instructions provided. QBREXZA should not be used on broken or irritated skin, and should not be used by individuals who have a history of sensitivity to glycopyrrolate or other anticholinergic medications.
Clinical studies have demonstrated the effectiveness of QBREXZA in reducing sweating in individuals with primary axillary hyperhidrosis. In these studies, QBREXZA was shown to significantly reduce sweat production and improve patients’ quality of life. QBREXZA’s safety profile appears to be favorable, with most side effects being mild to moderate in severity and primarily limited to the skin in the treated area.
Overall, QBREXZA appears to be a promising treatment option for individuals with primary axillary hyperhidrosis who have not found relief from other treatments. However, as with any medication, individuals considering treatment with QBREXZA should consult with their healthcare provider to determine if it is the right choice for their particular situation.
Frequently Asked Questions about qbrexza
This form of glycopyrronium is used to treat excessive sweating from your underarms. The drug solution is on a pre-moistened cloth for application to the skin. It works on the sweat glands to reduce sweating. Glycopyrronium belongs to a class of drugs known as anticholinergics.
In June, Dermira Inc. announced the FDA approval of Qbrexza (glycopyrronium) for primary axillary hyperhidrosis ― excessive underarm sweating. It is the first FDA-approved topical for this condition and may be available as a prescription treatment for pediatric and adult patients later this year.
Qbrexza User Reviews & Ratings (Page 2) Qbrexza has an average rating of 5.5 out of 10 from a total of 46 reviews on Drugs.com. 38% of reviewers reported a positive experience, while 36% reported a negative experience.
Mechanism of Action
Qbrexza (glycopyrronium) is a competitive inhibitor of acetylcholine receptors that are located on certain peripheral tissues, including sweat glands. In hyperhidrosis, glycopyrronium inhibits the action of acetylcholine on sweat glands, reducing sweating.
QBREXZA (glycopyrronium) cloth, 2.4%, is a prescription medication used on the skin to treat excessive underarm sweating (primary axillary hyperhidrosis) in people 9 years of age and older.
Journey Medical Corporation, a partner company of Fortress Biotech, Inc., has entered into a definitive agreement to acquire Qbrexza (glycopyrronium) in the US from Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company. The transaction is expected to close early in the second quarter of this year.
Established safety profile
QBREXZA is aluminum-free, and is proven to be safe and effective for patients 9 years and older with an excessive sweating condition.
While using Qbrexza (glycopyrronium), your body sweats less, and when exposed to high temperatures, you're at serious risk for overheating and having a heat stroke. Stop using this medication if you notice you're sweating less under these conditions, especially in parts of your body other than your underarms.
What is Qbrexza? Qbrexza is a prescription anticholinergic medicine used on the skin (topical) to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children 9 years of age and older. It is not known if Qbrexza is safe and effective in children under 9 years of age.
Other side effects of Qbrexza
- Dry mouth.
- fever.
- headache.
- increased sensitivity of the eyes to light.
- muscle aches.
- pain in the mouth or throat.
- redness, burning, stinging, or itching of the skin.
- sore throat.
Qbrexza is owned by Journey Medical Corporation, headquartered in Scottsdale, Arizona.
Please see full Prescribing Information, including Patient Product Information. QBREXZA is a registered trademark of Journey Medical Corporation.
If a hyperhidrosis prescription is appropriate, your out-of-pocket medication cost will depend on your insurance and where you decide to get your prescription filled. With a drug discount card, prices for Qbrexza 2.4 % Towelette (30 towelette packet) start at $664.05. * Prices shown with drug discount card applied.
